A prospective, multi-center, real-world study of apatinib mesylate in the treatment of gastric cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000035597

Enrollment

Unknown

Registered

2020-08-14

Start date

2020-09-01

Completion date

Unknown

Last updated

2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric

Interventions

Single group:apatinib

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Male or female patients, aged >= 18 years; 2. Patients with HER2 negative gastric or gastroesophageal junction adenocarcinoma confirmed by histology or cytology; 3. The researchers assessed that the patients could benefit from the treatment of apatinib; 4. Patients can understand and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients who have been proved to be allergic to apatinib mesylate tablets and / or its excipients; 2. Pregnant or lactating women; 3. Patients with contraindications of apatinib were excluded; 4. Patients who are considered unsuitable for inclusion by doctors.

Design outcomes

Primary

Measure	Time frame
MPR;DFS;PFS;	—

Secondary

Measure	Time frame
R0 resection rate;R1 resection rate;ORR;DCR;DOR;One-year OS rate;OS;Two-year OS rate;AE;	—

Countries

China

Contacts

Public ContactJianping Xiong, Jianwei Yang

The First Affiliated Hospital of Nanchang University/ Fujian Cancer Hospital

13879109229@163.com+86 13879109229; +86 13805097959

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026